Therapeutic strategies to address monkeypox

References

• Nicholas AH. A poxvirus of primates. II. immunology. J Natl Cancer Inst. 1970;45(5):907–914.
   PubMedGoogle Scholar
• Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593–597.
   PubMed Web of Science ®Google Scholar
• Anderson MG, Frenkel LD, Homann S, et al. A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. Pediatr Infect Dis J. 2003;22(12):1093–1096. discussion 6-8.
   PubMed Web of Science ®Google Scholar
• Hill B. The 2022 multinational monkeypox outbreak in non-endemic countries. Br J Nurs. 2022;31(12):664–665.
   PubMedGoogle Scholar
• Ahmed M, Naseer H, Arshad M, et al. Monkeypox in 2022: a new threat in developing. Ann Med Surg (Lond). 2022;78:103975.
   PubMed Web of Science ®Google Scholar
• Graham F. Daily briefing: how monkeypox might be spreading in sexual networks. Nature. 2022;1131–1139.
   Google Scholar
• Lourie B, Bingham PG, Evans HH, et al. Human infection with monkeypox virus: laboratory investigation of six cases in West Africa. Bull World Health Organ. 1972;46(5):633–639.
   PubMed Web of Science ®Google Scholar
• Foster SO, Brink EW, Hutchins DL, et al. Human monkeypox. Bull World Health Organ. 1972;46(5):569–576.
   PubMed Web of Science ®Google Scholar
• Patrocinio-Jesus R, Peruzzu F. Monkeypox genital lesions. N Engl J Med. 2022;387(1):66.
   PubMed Web of Science ®Google Scholar
• Bunge EM, Hoet B, Chen L, et al., The changing epidemiology of human monkeypox-A potential threat? A systematic review. Plos Negl Trop Dis. 2022;16(2):e0010141.
   PubMed Web of Science ®Google Scholar
• Lewis-Jones S. Zoonotic poxvirus infections in humans. Curr Opin Infect Dis. 2004;17(2):81–89.
   PubMed Web of Science ®Google Scholar
• Saxena SK, Ansari S, Maurya VK, et al. Re-emerging human monkeypox: a major public-health debacle. J Med Virol. 2022. DOI:10.1002/jmv.27902.
   Web of Science ®Google Scholar
• Russo AT, Grosenbach DW, Chinsangaram J, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021;19(3):331–344.
   PubMed Web of Science ®Google Scholar
• Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005;79(20):13139–13149.
   PubMed Web of Science ®Google Scholar
• Bolken TC, Hruby DE. Tecovirimat for smallpox infections. Drugs Today (Barc). 2010;46(2):109–117.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Historical perspectives in the development of antiviral agents against poxviruses. Viruses. 2010;2(6):1322–1339.
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Buller RM, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007;51(2):689–695.
   PubMed Web of Science ®Google Scholar
• Sbrana E, Jordan R, Hruby DE, et al. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg. 2007;76(4):768–773.
   PubMed Web of Science ®Google Scholar
• Jordan R, Tien D, Bolken TC, et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother. 2008;52(5):1721–1727.
   PubMed Web of Science ®Google Scholar
• Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother. 2012;56(9):4900–4905.
   PubMed Web of Science ®Google Scholar
• Nakoune E, Olliaro P. Waking up to monkeypox. BMJ. 2022;377:o1321.
   PubMedGoogle Scholar
• Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;22(8):1153–1162.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tecovirimat: first global approval. Drugs. 2018;78(13):1377–1382.
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53.
   PubMed Web of Science ®Google Scholar
• Melamed S, Israely T, Paran N. Challenges and achievements in prevention and treatment of smallpox. Vaccines (Basel). 2018;6(1). DOI:10.3390/vaccines6010008
   PubMed Web of Science ®Google Scholar
• Laudisoit A, Tepage F, Colebunders R. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(21):2084–2085.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–1236.
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother. 2007;51(11):4118–4124.
   PubMed Web of Science ®Google Scholar
• Stabenow J, Buller RM, Schriewer J, et al. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol. 2010;84(8):3909–3920.
   PubMed Web of Science ®Google Scholar
• Rice AD, Adams MM, Wallace G, et al. Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3(1):47–62.
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. New drug on the horizon for treating adenovirus. Expert Opin Pharmacother. 2015;16(14):2095–2099.
   PubMed Web of Science ®Google Scholar
• Whitmer SL, Albariño C, Shepard SS, et al. Preliminary evaluation of the effect of investigational ebola virus disease treatments on viral genome sequences. J Infect Dis. 2016;214(suppl 3):S333–S41.
   PubMedGoogle Scholar
• Vora SB, Brothers AW, Englund JA. Renal toxicity in pediatric patients receiving cidofovir for the treatment of adenovirus infection. J Pediatric Infect Dis Soc. 2017;6(4):399–402.
   PubMed Web of Science ®Google Scholar
• Voigt S, Hofmann J, Edelmann A, et al. Brincidofovir clearance of Acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. Transpl Infect Dis. 2016;18(5):791–794.
   PubMed Web of Science ®Google Scholar
• Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3(2):63–82.
   PubMed Web of Science ®Google Scholar
• Xiao SY, Sbrana E, Watts DM, et al. Experimental infection of prairie dogs with monkeypox virus. Emerg Infect Dis. 2005;11(4):539–545.
   PubMed Web of Science ®Google Scholar
• Weiner ZP, Salzer JS, LeMasters E, et al. Characterization of Monkeypox virus dissemination in the black-tailed prairie dog (Cynomys ludovicianus) through in vivo bioluminescent imaging. Plos One. 2019;14(9):e0222612.
   PubMed Web of Science ®Google Scholar
• Hutson CL, Kondas AV, Mauldin MR, et al. Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. mSphere. 2021;6(1):667–678.
   Web of Science ®Google Scholar
• Chavda VP, Apostolopoulos V. Rare monkeypox: is it really a threat to the elderly? Maturitas. 2022;163:90–91.
   PubMed Web of Science ®Google Scholar
• Brockmeyer NH. As monkeypox goes sexual: a public health perspective. J Eur Acad Dermatol Venereol. 2022;36(8):1164–1166.
   PubMed Web of Science ®Google Scholar
• Taseen S, Nasir F, Abbas M, et al. Post-pandemic world at the mercy of Monkeypox virus outbreak: time to worry or not? J Med Virol. 2022. DOI:10.1002/jmv.27948
   PubMed Web of Science ®Google Scholar
• Zachary KC, Shenoy ES. Monkeypox transmission following exposure in healthcare facilities in nonendemic settings: low risk but limited literature. Infect Control Hosp Epidemiol. 2022;19:1–5.
   Google Scholar
• Rao AK, Schulte J, Chen TH, et al. Monkeypox in a traveler returning from Nigeria - Dallas, Texas. MMWR Morb Mortal Wkly Rep. 2021 Jul;71(14):509–516.
   Web of Science ®Google Scholar
• Mileto D, Riva A, Cutrera M, et al. New challenges in human monkeypox outside Africa: a review and case report from Italy. Travel Med Infect Dis. 2022;49:102386.
   PubMed Web of Science ®Google Scholar
• Isidro J, Borges V, Pinto M, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022. DOI:10.1038/s41591-022-01907-y.
   PubMed Web of Science ®Google Scholar
• Collignon O, Burman CF, Posch M, et al. Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome. Clin Pharmacol Ther. 2021;110(2):311–320.
   PubMed Web of Science ®Google Scholar
• Dodd LE, Freidlin B, Korn EL. Platform trials - Beware the noncomparable control group. N Engl J Med. 2021;384(16):1572–1573.
   PubMed Web of Science ®Google Scholar
• Freidlin B, Korn EL, Gray R, et al. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008;14(14):4368–4371.
   PubMed Web of Science ®Google Scholar
• Murray DD, Babiker AG, Baker JV, et al. Design and implementation of the multi-arm, multi-stage therapeutics for inpatients with COVID-19 (TICO) platform master protocol: an accelerating COVID-19 therapeutic interventions and vaccines (ACTIV) initiative. medRxiv. 2020.
   Google Scholar
• Thabane L, Lancaster G. Improving the efficiency of trials using innovative pilot designs: the next phase in the conduct and reporting of pilot and feasibility studies. Pilot Feasibility Stud. 2018;4(1):14.
   PubMedGoogle Scholar
• Challenger A, Sumner P, Bott L. COVID-19 myth-busting: an experimental study. BMC Public Health. 2022;22(1):131.
   PubMedGoogle Scholar
• Ghaddar A, Khandaqji S, Awad Z, et al. Conspiracy beliefs and vaccination intent for COVID-19 in an infodemic. Plos One. 2022;17(1):e0261559.
   PubMed Web of Science ®Google Scholar
• Briand SC, Cinelli M, Nguyen T, et al. Infodemics: a new challenge for public health. Cell. 2021;184(25):6010–6014.
   PubMed Web of Science ®Google Scholar
• Quarleri J, Delpino MV, Galvan V. Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. Geroscience. 2022. DOI:10.1007/s11357-022-00611-6
   Web of Science ®Google Scholar
• Mahase E. Monkeypox: healthcare workers will be offered smallpox vaccine as UK buys 20 000 doses. BMJ. 2022;377:o1379.
   PubMedGoogle Scholar
• Kozlov M. Monkeypox goes global: why scientists are on alert. Nature. 2022;606(7912):15–16.
   PubMed Web of Science ®Google Scholar
• Mahase E. Monkeypox: gay and bisexual men with high exposure risk will be offered vaccine in England. BMJ. 2022;377:o1542.
   PubMedGoogle Scholar
• Vivancos R, Anderson C, Blomquist P, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022;27(22). DOI:10.2807/1560-7917.ES.2022.27.22.2200422.
   Google Scholar
• Wenham C, Kavanagh M, Phelan A, et al. Problems with traffic light approaches to public health emergencies of international concern. Lancet. 2021;397(10287):1856–1858.
   PubMed Web of Science ®Google Scholar